Benzinga··Vandana SinghEli Lilly's Omvoh Demonstrates Three-Year Remission Durability in Crohn's Disease
Eli Lilly's Omvoh shows durable three-year remission in Crohn's disease, with 92.4% of patients maintaining clinical remission and reduced hospitalizations compared to placebo.
LLYFDA approvalPhase 3 trial